Health Care Professionals Log In

Patient Education Materials

At Wyeth, we know that educating patients about a therapy such as LYBREL® is a responsibility that falls largely into the hands of health care professionals like you. That's why we’ve created educational materials for your patients to help them gain a better understanding of LYBREL.

Click on any of the links to download and print the materials listed below.

Is LYBREL Right for You? Requires Adobe® Reader®
A series of self-assessment statements for patients to consider if they're thinking about taking LYBREL.

Questions Frequently Asked by Patients About LYBREL. Requires Adobe® Reader®
Patient-friendly answers to common questions about LYBREL.

Starting LYBREL. Requires Adobe® Reader®
Information for your patients on how to start taking LYBREL, including a step-by-step guide on using the ClickCase™.

Progress Tracker. Requires Adobe® Reader®
Daily and monthly worksheets for patients to monitor what type of bleeding, if any, they experience while taking LYBREL and to make note of any changes in bleeding.

Patient Package Insert. Requires Adobe® Reader®
Consumer-language version of the prescribing information for LYBREL.

Get Adobe® Reader®

Prescribing LYBREL

Information, tips, and support to help you prescribe LYBREL to the appropriate patients and manage patient expectations.

Important Safety Information

  • Oral contraceptives (OCs) do not protect against HIV infection or other sexually transmitted diseases.
  • When prescribing LYBREL, the convenience of having no scheduled menstrual bleeding should be weighed against the inconvenience of unscheduled breakthrough bleeding and spotting.
  • OCs are contraindicated in women who have blood clots; breast, uterine, or liver cancers; a history of heart attack, stroke, or breast cancer; as well as those who are or may be pregnant.
The risks of serious cardiovascular side effects are substantially increased in women who smoke and use OCs, especially in women over age 35. Women who use oral contraceptives should be strongly advised not to smoke.
  • Serious risks associated with OCs include blood clots, heart attack, and stroke.
  • LYBREL provides women with more hormonal exposure on a yearly basis (13 additional weeks of hormone intake per year) than conventional cyclic oral contraceptives containing the same strength of synthetic estrogens and similar strength of progestins.
  • Scheduled withdrawal bleeding does not occur with the use of LYBREL, therefore, the absence of withdrawal bleeding cannot be used as a sign of an unexpected pregnancy and as such, unexpected pregnancy may be difficult to recognize. Although pregnancy is unlikely if LYBREL is taken as directed, if for any reason, pregnancy is suspected in a woman using LYBREL, a pregnancy test should be performed.
  • The most commonly reported treatment emergent adverse events reported with LYBREL in a clinical trial were headache, dysmenorrhea, upper respiratory infection, vaginal bleeding (defined as metrorrhagia and vaginal hemorrhage), and nausea.

Registration | Unsubscribe | E-mail This Page | Patient Awareness | Patient Support Program | References

206810-01

LYBREL and LYBREL with icon are registered trademarks of Wyeth.